Tags

Type your tag names separated by a space and hit enter

Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial.

Abstract

To investigate the effects of treatment with Myo-inositol (an insulin sensitizing drug), on circulating insulin, glucose tolerance, ovulation and serum androgens concentrations in women with the Polycystic Ovary Syndrome (PCOS). Forty-two women with PCOS were treated in a double-blind trial with Myo-inositol plus folic acid or folic acid alone as placebo. In the group treated with Myo-inositol the serum total testosterone decreased from 99.5 +/- 7 to 34.8 +/- 4.3 ng/dl (placebo group: from 116.8 +/- 15 to 109 +/- 7.5 ng/dl; P = 0.003), and serum free testosterone from 0.85 +/- 0.1 to 0.24 +/- 0.33 ng/dl (placebo group: from 0.89 +/- 0.12 to 0.85 +/- 0.13 ng/dl; P = 0.01). Plasma triglycerides decreased from 195 +/- 20 to 95 +/- 17 mg/dl (placebo group: from 166 +/- 21 to 148 +/- 19 mg/dl; P = 0.001). Systolic blood pressure decreased from 131 +/- 2 to 127 +/- 2 mmHg (placebo group: from 128 +/- 1 to 130 +/-1 mmHg; P = 0.002). Diastolic blood pressure decreased from 88 +/- 1 to 82 +/- 3 mmHg (placebo group: from 86 +/- 1 to 90 +/- 1 mmHg; P = 0.001). The area under the plasma insulin curve after oral administration of glucose decreased from 8.54 +/- 1.149 to 5.535 +/- 1.792 microU/ml/min (placebo group: from 8.903 +/- 1.276 to 9.1 +/- 1.162 microU/ml/min; P = 0.03). The index of composite whole body insulin sensitivity (ISI comp) increased from 2.80 +/- 0.35 to 5.05 +/- 0.59 mg(-2)/dl(-2) (placebo group: from 3.23 +/- 0.48 to 2.81 +/- 0.54 mg(-2)/dl(-2); P < 0.002). 16 out of 23 women of Myo-inositol group ovulated (4 out of 19 in placebo group). Treatment of PCOS patients with Myo-inositol provided a decreasing of circulating insulin and serum total testosterone as well as an improvement in metabolic factors.

Authors+Show Affiliations

,

Centro Salute della Donna, Azienda USL, Ferrara, Italy. kostin@alice.it

, ,

Source

MeSH

Adolescent
Adult
Area Under Curve
Blood Pressure
Double-Blind Method
Drug Therapy, Combination
Female
Folic Acid
Humans
Inositol
Insulin
Ovulation
Polycystic Ovary Syndrome
Testosterone
Triglycerides
Vitamin B Complex
Young Adult

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

19499845

Citation

Costantino, D, et al. "Metabolic and Hormonal Effects of Myo-inositol in Women With Polycystic Ovary Syndrome: a Double-blind Trial." European Review for Medical and Pharmacological Sciences, vol. 13, no. 2, 2009, pp. 105-10.
Costantino D, Minozzi G, Minozzi E, et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009;13(2):105-10.
Costantino, D., Minozzi, G., Minozzi, E., & Guaraldi, C. (2009). Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. European Review for Medical and Pharmacological Sciences, 13(2), pp. 105-10.
Costantino D, et al. Metabolic and Hormonal Effects of Myo-inositol in Women With Polycystic Ovary Syndrome: a Double-blind Trial. Eur Rev Med Pharmacol Sci. 2009;13(2):105-10. PubMed PMID: 19499845.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. AU - Costantino,D, AU - Minozzi,G, AU - Minozzi,E, AU - Guaraldi,C, PY - 2009/6/9/entrez PY - 2009/6/9/pubmed PY - 2009/6/26/medline SP - 105 EP - 10 JF - European review for medical and pharmacological sciences JO - Eur Rev Med Pharmacol Sci VL - 13 IS - 2 N2 - To investigate the effects of treatment with Myo-inositol (an insulin sensitizing drug), on circulating insulin, glucose tolerance, ovulation and serum androgens concentrations in women with the Polycystic Ovary Syndrome (PCOS). Forty-two women with PCOS were treated in a double-blind trial with Myo-inositol plus folic acid or folic acid alone as placebo. In the group treated with Myo-inositol the serum total testosterone decreased from 99.5 +/- 7 to 34.8 +/- 4.3 ng/dl (placebo group: from 116.8 +/- 15 to 109 +/- 7.5 ng/dl; P = 0.003), and serum free testosterone from 0.85 +/- 0.1 to 0.24 +/- 0.33 ng/dl (placebo group: from 0.89 +/- 0.12 to 0.85 +/- 0.13 ng/dl; P = 0.01). Plasma triglycerides decreased from 195 +/- 20 to 95 +/- 17 mg/dl (placebo group: from 166 +/- 21 to 148 +/- 19 mg/dl; P = 0.001). Systolic blood pressure decreased from 131 +/- 2 to 127 +/- 2 mmHg (placebo group: from 128 +/- 1 to 130 +/-1 mmHg; P = 0.002). Diastolic blood pressure decreased from 88 +/- 1 to 82 +/- 3 mmHg (placebo group: from 86 +/- 1 to 90 +/- 1 mmHg; P = 0.001). The area under the plasma insulin curve after oral administration of glucose decreased from 8.54 +/- 1.149 to 5.535 +/- 1.792 microU/ml/min (placebo group: from 8.903 +/- 1.276 to 9.1 +/- 1.162 microU/ml/min; P = 0.03). The index of composite whole body insulin sensitivity (ISI comp) increased from 2.80 +/- 0.35 to 5.05 +/- 0.59 mg(-2)/dl(-2) (placebo group: from 3.23 +/- 0.48 to 2.81 +/- 0.54 mg(-2)/dl(-2); P < 0.002). 16 out of 23 women of Myo-inositol group ovulated (4 out of 19 in placebo group). Treatment of PCOS patients with Myo-inositol provided a decreasing of circulating insulin and serum total testosterone as well as an improvement in metabolic factors. SN - 1128-3602 UR - https://www.unboundmedicine.com/medline/citation/19499845/Metabolic_and_hormonal_effects_of_myo_inositol_in_women_with_polycystic_ovary_syndrome:_a_double_blind_trial_ L2 - https://ClinicalTrials.gov/search/term=19499845 [PUBMED-IDS] DB - PRIME DP - Unbound Medicine ER -